Gene synthesis giant, Genscript, has recently entered into a strategic cooperation agreement with Selecxine, a biotech startup focusing on drug discovery.
The agreement is set to provide Selecxine with Genscript`s gene synthesis and custom protein production services to aid in their drug discovery research and development efforts.
This partnership is poised to bring about exciting advancements in the field of biotech, combining the expertise and technology of both companies. Genscript has a strong track record in gene synthesis, custom protein production, and life science research, while Selecxine is well-versed in drug discovery and has a portfolio of innovative drug candidates.
Gene synthesis is crucial in drug discovery research, as it allows scientists to create custom DNA sequences to precisely engineer proteins and other biological molecules. This can be utilized in various applications, such as developing new drugs or vaccines.
By partnering with Genscript, Selecxine can leverage the company`s expertise and technology to accelerate their research and development efforts. As Genscript is a leading provider of gene synthesis and custom protein production services, this partnership will enable Selecxine to access a wide range of tools and expertise to accelerate their drug discovery pipelines.
Furthermore, Genscript`s established global presence will provide Selecxine with access to a broad range of strategic partnerships and collaborations around the world.
In conclusion, the recent cooperation agreement between Genscript and Selecxine is an exciting development for the biotech industry. By combining their strengths and resources, both companies can leverage the latest tools and technologies to advance their research and development efforts and ultimately bring new therapies to patients in need.
